
Integra LifeSciences Holdings Corporation
IARTNASDAQHealthcareMedical - Devices
Previous close
$16.74
+$0.15 · +0.90%
IART company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Hold
Wait — insufficient conviction to act
Valuation
63
Undervalued
Momentum
70
Gaining
Sentiment
64
Bullish
Risk resilience
59
Elevated Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteIntegra LifeSciences Holdings Corporation is a medical technology company focused on the creation, production, and global distribution of advanced surgical implants and instruments. These products are utilized across various medical fields, including neurosurgery, limb reconstruction, and general surgical procedures. The company operates through two primary business segments: Codman Specialty Surgical and Tissue Technologies. The Codman Specialty Surgical division offers a comprehensive range of neurosurgical and neuro-critical care products. This includes specialized equipment for tissue ablation, dural repair solutions, cerebral spinal fluid management systems, intracranial monitoring tools, and cranial stabilization devices. Additionally, this segment provides surgical headlamps, various instrumentation, and supports these offerings with asset management software, technical assistance, and after-market services. Integra also supplies an extensive catalog of approximately 40,000 surgical instrument designs, along with a wide selection of surgical and lighting products. Its clientele spans hospitals, surgical centers, and extends to dental, podiatry, and veterinary practices. The Tissue Technologies segment specializes in innovative regenerative technology products for the treatment of both acute and chronic wounds. It further provides surgical tissue repair solutions for a multitude of applications, such as hernia repair, peripheral nerve protection and regeneration, and tendon reconstruction. This encompasses a broad array of offerings for skin and wound repair, plastic and reconstructive surgery products, bone grafting materials, and specialized nerve and tendon repair products. Integra LifeSciences distributes its diverse product portfolio internationally, reaching markets throughout the United States, Europe, Asia Pacific, and other global regions. Distribution is managed directly through its dedicated sales forces and various other channels, serving a wide array of healthcare entities including hospitals, integrated health networks, group purchasing organizations, individual clinicians, surgery centers, and other healthcare providers. Founded in 1989, Integra LifeSciences Holdings Corporation is headquartered in Princeton, New Jersey.
- Industry
- Medical - Devices
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Stuart Essig
- Listed since
- Aug 16, 1995
- Employees
- 4,427
Market position
Day range
Current $16.74
52-week range
Current $16.74
- Open
- $16.81
- Previous close
- $16.59
- Volume
- 551.8K
- 0.57× average
- Average volume
- 973.79K
- Average daily volume
- Market cap
- 1.3B USD
- Beta
- 1.21
- Market reference 1
- 50-day average
- $17.9878
- -6.94% below average
- 200-day average
- $13.5363
- +23.67% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 2.75B USD
- P/E (TTM)
- -181.56×
- P/B (TTM)
- 1.25×
- P/S (TTM)
- 0.79×
- EV / EBITDA
- -8.43×
- Earnings yield
- -54.18%
- Free cash flow yield
- -4.75%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 53.74%
- Operating margin
- 39.81%
- Net margin
- -0.44%
- Return on equity
- -49.50%
- Return on assets
- -14.34%
- Return on invested capital
- 1.91%
Financial health
- Debt / equity
- 1.94×
- Current ratio
- 2.54×
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1.64B USD | 1.61B USD | 1.54B USD | 1.56B USD | 1.54B USD |
| Cost of goods sold | 790.01M USD | 728.47M USD | 656.84M USD | 587.36M USD | 597.81M USD |
| Gross profit | 845.23M USD | 882.06M USD | 884.74M USD | 970.31M USD | 944.64M USD |
| Research and development | 98.97M USD | 115.38M USD | 104.19M USD | 101.19M USD | 93.05M USD |
| Selling, general, and administrative | 699.7M USD | 716.98M USD | 656.64M USD | 616.32M USD | 637.45M USD |
| Operating expenses | 776.92M USD | 853.65M USD | 773.21M USD | 731.39M USD | 747.41M USD |
| Interest income | 18.47M USD | 20.04M USD | 17.2M USD | 11.92M USD | 6.74M USD |
| Interest expense | 86.26M USD | 70.63M USD | 51.38M USD | 49.59M USD | 50.4M USD |
| Depreciation and amortization | 151.05M USD | 140.5M USD | 123.51M USD | 121.12M USD | 123.67M USD |
| Operating income | 68.32M USD | 28.41M USD | 111.53M USD | 238.92M USD | 197.23M USD |
| Net income | −516.47M USD | −6.94M USD | 67.74M USD | 180.55M USD | 169.08M USD |
Company facts updated Aug 24, 2026.
IART peers
ETFs holding IART
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Core S&P Small-Cap ETFIJR71.93M0.06%111.19B USD0.06%$147.31—
Vanguard Morningstar Total Stock Market ETFVTI35.1M0.00%2.3T USD0.03%$378.24—
iShares Russell 2000 ETFIWM29.09M0.04%81.62B USD0.19%$299.96—
Vanguard Morningstar Small-Cap ETFVB25.3M0.01%183.4B USD0.03%$304.76—
Vanguard Morningstar Small-Cap Value ETFVBR16.08M0.02%68.3B USD0.05%$249.18—
Vanguard Extended Market ETFVXF12.84M0.01%93.7B USD0.05%$245.53—
iShares S&P Small-Cap 600 Value ETFIJS10.57M0.13%8.33B USD0.18%$138.43—
iShares Russell 2000 Value ETFIWN10.5M0.07%14.66B USD0.24%$224.81—
iShares Core S&P Small-Cap ETFIJR- Market value
- 71.93M
- Weight
- 0.06%
- AUM
- 111.19B USD
- Expense ratio
- 0.06%
- Price / 1D
- $147.31—
Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 35.1M
- Weight
- 0.00%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $378.24—
iShares Russell 2000 ETFIWM- Market value
- 29.09M
- Weight
- 0.04%
- AUM
- 81.62B USD
- Expense ratio
- 0.19%
- Price / 1D
- $299.96—
Vanguard Morningstar Small-Cap ETFVB- Market value
- 25.3M
- Weight
- 0.01%
- AUM
- 183.4B USD
- Expense ratio
- 0.03%
- Price / 1D
- $304.76—
Vanguard Morningstar Small-Cap Value ETFVBR- Market value
- 16.08M
- Weight
- 0.02%
- AUM
- 68.3B USD
- Expense ratio
- 0.05%
- Price / 1D
- $249.18—
Vanguard Extended Market ETFVXF- Market value
- 12.84M
- Weight
- 0.01%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $245.53—
iShares S&P Small-Cap 600 Value ETFIJS- Market value
- 10.57M
- Weight
- 0.13%
- AUM
- 8.33B USD
- Expense ratio
- 0.18%
- Price / 1D
- $138.43—
iShares Russell 2000 Value ETFIWN- Market value
- 10.5M
- Weight
- 0.07%
- AUM
- 14.66B USD
- Expense ratio
- 0.24%
- Price / 1D
- $224.81—
Continue in GoAI
Research IARTresearch.disclaimer





